76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
GlycoMimetics Inc
Closed
SectorHealthcare
0.15
Overview
Share price change
24h
Min
0.13
Max
0.15
Income | -2.3B -2.3B |
|---|---|
EPS | -0.04 |
Profit margin | -13,354.199 |
Employees | 4 |
EBITDA | 2.9M -2.4M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +43.79% upside |
Market Cap | 10M |
|---|---|
Previous open | 0.15 |
Previous close | 0.15 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
GlycoMimetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
GlycoMimetics Inc Forecast
Price Target
By TipRanks
43.79% upside
12 Months Forecast
Average 22 USD 43.79%
High 22 USD
Low 22 USD
Based on 2 Wall Street analysts offering 12 month price targets forGlycoMimetics Inc - Dist in the last 3 months.
Financials
$
About GlycoMimetics Inc
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
